Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Pharm Sci ; 104(5): 1677-90, 2015 May.
Article in English | MEDLINE | ID: mdl-25652269

ABSTRACT

The overall study goal was to produce a microparticle formulation containing atropine sulfate for ocular administration with improved efficacy and lower side effects, compared with that of the standard marketed atropine solution. The objective was to prepare an atropine sulfate-loaded bovine serum albumin-chitosan microparticle that would have longer contact time on the eyes as well as better mydriatic and cycloplegic effect using a rabbit model. The microparticle formulation was prepared by method of spray-drying technique. The percent drug loading and encapsulation efficiency were assessed using a USP (I) dissolution apparatus. The particle sizes and zeta potential were determined using laser scattering technique and the surface morphology of the microparticles was determined using a scanning electron microscope. The product yield was calculated from relative amount of material used. In vitro cytotoxicity and uptake by human corneal epithelial cells were examined using AlamarBlue and confocal microscopy. The effects of the microparticle formulation on mydriasis in comparison with the marketed atropine sulfate solution were evaluated in rabbit eyes. The prepared microparticle formulation had ideal physicochemical characteristics for delivery into the eyes. The in vivo studies showed that the microparticles had superior effects on mydriasis in rabbits than the marketed solutions


Subject(s)
Atropine/chemical synthesis , Chitosan/chemical synthesis , Cornea , Drug Delivery Systems/methods , Microspheres , Serum Albumin, Bovine/chemical synthesis , Animals , Atropine/administration & dosage , Atropine/metabolism , Cattle , Cells, Cultured , Chemistry, Pharmaceutical , Chitosan/administration & dosage , Chitosan/metabolism , Cornea/drug effects , Cornea/metabolism , Eye/drug effects , Eye/metabolism , Humans , Mydriasis/drug therapy , Mydriasis/metabolism , Rabbits , Serum Albumin, Bovine/administration & dosage , Serum Albumin, Bovine/metabolism
2.
J Drug Target ; 22(1): 34-47, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23987115

ABSTRACT

PURPOSE: Oral immunization for mucosal protection against Mycobacterium tuberculosis would be the best option for effective tuberculosis (TB) control. However, this route of vaccine delivery is limited due to the short residence time of the delivery system at the site of absorption. Cytoadhension has made it possible to optimize the targeted delivery of oral vaccine to lymphoid tissues. The purpose of this project was to evaluate the ability of human M-cell specific lectin-labeled microparticles to target the human M-cells of the Peyer's patches. METHOD: Albumin microspheres containing Mycobacterium tuberculosis cell lysate antigens were coupled with Wheat germ agglutinin and Aleuria aurantia lectins and their ability to bind to M cell models as well as their preferential distribution in the Peyer's patches were investigated. RESULTS: The study demonstrated an enhanced delivery of targeted polystyrene and BSA/Lysate microspheres to M cells. It was demonstrated that alpha-l-fucose sugar residue might be the target of these lectins. CONCLUSION: It can be concluded from the study that the lectin-coupled microspheres had better affinity for M-cells and showed preferential binding to the Peyer's patches. This means that the coupling enhanced the targeted delivery of the antigens to the M cells.


Subject(s)
Antigens, Bacterial/administration & dosage , Antigens, Bacterial/chemistry , BCG Vaccine/administration & dosage , BCG Vaccine/chemistry , Lectins/administration & dosage , Lectins/chemistry , Administration, Oral , Albumins/immunology , Alkaline Phosphatase/metabolism , Animals , Antigens, Bacterial/immunology , BCG Vaccine/immunology , Caco-2 Cells , Cell Line, Tumor , Drug Delivery Systems/methods , Fucose/administration & dosage , Fucose/chemistry , Fucose/immunology , Humans , Lectins/immunology , Mice , Microspheres , Mycobacterium tuberculosis/immunology , Mycobacterium tuberculosis/metabolism , Peyer's Patches/immunology , Polystyrenes/administration & dosage , Polystyrenes/chemistry , Polystyrenes/immunology , Tuberculosis/prevention & control
3.
J Drug Target ; 17(9): 701-9, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19845486

ABSTRACT

UNLABELLED: Microencapsulated (MC) catalase has been shown to inhibit H(2)O(2) and tumor necrosis factor (TNF) in vitro after endotoxin stimulation. It is the purpose of this study to determine whether MC catalase improves pro-inflammatory cytokine inhibition and mortality in an endotoxic shock model in vivo. We also examined whether MC catalase and antisense oligonucleotides (ASO) to nuclear factor kappaB (NF-kappaB) together improved survival by inhibiting pro-inflammatory cytokines using different mechanisms. METHODS: Albumin microcapsules containing catalase and ASO to NF-kappaB were prepared 2-7 microm in size by using a Büchi spray dryer. Progressively increasing doses of MC catalase, MC ASO to NF-kappaB, and the combination were given to rats before the administration of Escherichia coli endotoxin. Results demonstrated 60% survival in rats given 15 mg/kg MC catalase, 70% survival with 20 mg/kg MC ASO NF-kappaB, and 80% survival with the combination. TNF was inhibited by 53% in the MC catalase group 4 h after endotoxin administration, 43% in the ASO NF-kappaB group, and 78% in the combination group compared to controls. In conclusion, this study demonstrates the effectiveness of MC intracellular delivery of the naturally occurring antioxidant catalase in improving animal survival. The addition of ASO to NF-kappaB improved both cytokine inhibition and animal survival in endotoxic shock.


Subject(s)
Catalase/pharmacology , NF-kappa B/metabolism , Oligodeoxyribonucleotides, Antisense/pharmacology , Shock, Septic/drug therapy , Animals , Antioxidants/administration & dosage , Antioxidants/pharmacology , Catalase/administration & dosage , Cattle , Combined Modality Therapy , Cytokines/antagonists & inhibitors , Disease Models, Animal , Drug Carriers/chemistry , Endotoxins , Microspheres , Oligodeoxyribonucleotides, Antisense/administration & dosage , Particle Size , Rats , Rats, Sprague-Dawley , Serum Albumin, Bovine/chemistry , Shock, Septic/mortality , Shock, Septic/physiopathology , Survival Rate
4.
J Drug Target ; 17(9): 710-8, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19845487

ABSTRACT

UNLABELLED: Reactive oxygen species synthesized by endothelial cells may be responsible for cell damage and altered physiologic function. After endotoxin stimulation, free radicals including H(2)O(2) are produced. We have developed a method of intracellular drug delivery using albumin microcapsules. Catalase would be an excellent compound to alter H(2)O(2) production. However, the large molecular size of catalase limits cellular penetration. Endothelial cells have been previously shown to readily phagocytoze albumin microcapsules. METHODS: Catalase was added to an albumin solution to form a 10% solution of catalase. Microspheres from 2 to 7 microm in size were formed using a Bucchi spray dryer. Human endothelial cells were incubated with varying concentrations of microencapsulated catalase. The cells were then exposed to Escherichia coli endotoxin to determine if increased intracellular penetration of catalase would inhibit H(2)O(2), nitrate, and cytokine synthesis. RESULTS: There was a 7.2-fold increase in endothelial intracellular catalase after 48 h incubation. H(2)O(2) was inhibited by 72%, nitrate 96%, TNF 90%, IL1 21%, IL6 42%. CONCLUSIONS: These results demonstrate that inhibition of H(2)O(2) as a result of increased intracellular delivery of catalase inhibits proinflammatory cytokine synthesis after endotoxin exposure.


Subject(s)
Antioxidants/pharmacology , Catalase/pharmacology , Cytokines/antagonists & inhibitors , Hydrogen Peroxide/antagonists & inhibitors , Animals , Antioxidants/administration & dosage , Catalase/administration & dosage , Cattle , Cells, Cultured , Drug Carriers/chemistry , Endothelial Cells/metabolism , Endothelium, Vascular/cytology , Endothelium, Vascular/metabolism , Endotoxins , Humans , Microspheres , Particle Size , Reactive Oxygen Species/metabolism , Serum Albumin, Bovine/chemistry
5.
J Microencapsul ; 26(5): 411-9, 2009 Aug.
Article in English | MEDLINE | ID: mdl-18821261

ABSTRACT

Catalase in albumin microspheres were formulated for intravenous administration to antagonize the effects of over-production of reactive oxygenated species (ROS) such as hydrogen peroxide (H(2)O(2)) in septic shock. The aim was to increase effective half-life of catalase and take advantage of the phagocytic uptake of the encapsulated catalase by the vascular endothelium. Catalase microspheres were prepared by spray-drying. The microspheres were evaluated for particle size, particle shape and surface morphology by scanning electron microscopy (SEM), drug encapsulation efficiency, chemical stability, thermal stability and in vitro drug release characteristics. The microspheres had a mean particle size of 4.7 +/- 2 microm, optimal for phagocytic uptake, as demonstrated by Makino et al. SEM revealed that microspheres were spherical with smooth surface morphology. An encapsulation efficiency of 91.5 +/- 3% was achieved and the encapsulated catalase was chemically and thermally stable. Application of in vitro drug release data to the Higuchi kinetic equation indicated matrix diffusion-controlled catalase release from albumin microspheres.


Subject(s)
Albumins , Catalase , Chemistry, Pharmaceutical/methods , Drug Delivery Systems , Microspheres , Catalase/chemistry , Catalase/metabolism , Cell Line , Diffusion , Endothelial Cells/enzymology , Endothelium, Vascular/cytology , Humans , Particle Size , Temperature
SELECTION OF CITATIONS
SEARCH DETAIL
...